Oligosaccharide in Frauenmilch

详细信息    查看全文

• 作者：Prof. Dr. S. Rudloff ; C. Kunz
• 关键词：Humanmilch ; Lewis ; Blutgruppensystem ; Mikrobiota ; Supplementierung ; Bifidobacterium ; Human milk ; Lewis blood group system ; Microbiota ; Supplementation ; Bifidobacterium
• 刊名：Monatsschrift Kinderheilkunde
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：163
• 期：8
• 页码：790-795
• 全文大小：408 KB
• 参考文献：1.Kunz C, Rudloff S, Baier W, Klein N et al (2000) Oligosaccharides in human milk: structural, functional, and metabolic aspects. Ann Rev Nutr 20:699-22View Article
  2.Bode L (2012) Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 22:1147-162PubMed Central PubMed View Article
  3.Rudloff S, Kunz C (2012) Milk oligosaccharides and infant nutrition. Adv Nutr 3:398-05View Article
  4.Prieto PA (2012) Profiles of human milk oligosaccharides and production of some human milk oligosaccharides in transgenic animals. Adv Nutr 3:456S-64SPubMed Central PubMed View Article
  5.Schack-Nielsen L, Michaelsen KF (2007) Advances in our understanding of the biology of human milk and its effects on the offspring. J Nutr 137:503S-10SPubMed
  6.McGovern DP, Jones MR, Taylor KD et al (2010) Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn’s disease. Hum Mol Genet 19:3468-476PubMed Central PubMed View Article
  7.Tong M, McHardy I, Ruegger P et al (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn’s disease risk polymorphism. ISME J 8:2193-206PubMed View Article
  8.Morrow AL, Meinzen-Derr J, Huang P et al (2011) Fucosyltransferase 2 non-secretor and low secretor status predicts severe outcomes in premature infants. J Pediatr 158:745-51PubMed Central PubMed View Article
  9.Sela DA, Mills DA (2010) Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. Trends Microbiol 18:298-07PubMed Central PubMed View Article
  10.Kitaoka M (2012) Bifidobacterial enzymes involved in the metabolism of human milk oligosaccharides. Adv Nutr 3:422S-29SPubMed Central PubMed View Article
  11.Vázquez E, Barrancoa A, Ramíreza M et al (2015) Effects of a human milk oligosaccharide, 2-fucosyllactose, on hippocampal long-term potentiation and learning capabilities in rodents. J Nutr Biochem 26:455-65PubMed View Article
  12.Fuhrer A, Sprenger N, Kurakevich E et al (2010) Milk sialyllactose influences colitis in mice through selective intestinal bacterial colonization. J Exp Med 207:2843-854PubMed Central PubMed View Article
  13.Li M, Monaco MH, Wang M et al (2014) Human milk oligosaccharides shorten rotavirus-induced diarrhea and modulate piglet mucosal immunity and colonic microbiota. ISME J 8:1609-620PubMed View Article
  14.Ruiz-Palacios GM, Cervantes LE, Ramos P et al (2003) Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem 278:14112-4120PubMed View Article
  15.Jantscher-Krenn E, Zherebtsov M, Nissan C et al (2012) The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotising enterocolitis in neonatal rats. Gut 61:1417-425PubMed Central PubMed View Article
  16.Witt W, von Nicolai H, Zilliken F (1979) Uptake and distribution of orally applied N-acetyl-(14C)-neuraminyllactose and N-acetyl-(14C)-neuraminic acid in the organs of newborn rats. Nutr Metab 23:51-1PubMed View Article
  17.Carlson SE, House SG (1986) Oral and intraperitoneal administration of N-acetylneuraminic acid: effect on rat cerebral and cerebellar N-acetylneuraminic acid. J Nutr 116:881-86PubMed
  18.Wang B (2009) Sialic acid is an essential nutrient for brain development and cognition. Ann Rev Nutr 29:177-22View Article
  19.Hunt KM, Preuss J, Nissan C et al (2012) Human milk oligosaccharides promote the growth of staphylococci. Appl Environ Microbiol 78:4763-770PubMed Central PubMed View Article
  20.Kurakevich E, Hennet T, Hausmann M et al (2013) Milk oligosaccharide sialyl(α2,3)lactose activates intestinal CD11c+ cells through TLR4. Proc Natl Acad Sci U S A 110:17444-7449PubMed Central PubMed View Article
  
• 作者单位：Prof. Dr. S. Rudloff (1) (2)
  C. Kunz (2)
  
  1. Zentrum für Kinderheilkunde und Jugendmedizin, Justus-Liebig-Universit?t, Gie?en, Deutschland
  2. Institut für Ern?hrungswissenschaft, Justus-Liebig-Universit?t, Wilhelmstr. 20, 35392, Gie?en, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pediatrics
  General Practice and Family Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-0474

文摘

During the last decade great progress has been achieved regarding the characterization of individual human milk oligosaccharides (HMO) and different HMO patterns, which are currently under intensive investigation in the context of infant health. Human milk contains a variety of complex oligosaccharides in concentrations of 10-0?g/l and can thus be considered as the third most abundant class of components besides lactose and fat. Biosynthesis in the mammary glands is influenced by specific enzymes, which are also responsible for the Lewis blood group type and the secretor status. Previous studies indicated that HMOs modulate growth and activity of certain microorganisms, especially of some strains of bifidobacteria. Despite these interesting data which are primarily based on in vitro studies, the bifidogenic effect of HMOs in infants has not yet been clearly proven. This is also true for other specific functions of HMOs, such as their influence on inflammatory and infectious processes or the inhibitory effect on the adhesion of pathogens and their toxins to epithelial surfaces. Biotechnical advancements now enable the production of some HMOs on a large scale so that these components are currently being studied in vivo and might soon be used to supplement infant formula; however, prior to clinical studies it needs to be considered that single HMOs may exert different or even adverse biological effects than the complex mixture of HMOs found in human milk. In addition, HMOs may affect infants differently depending on the degree of maturation (i.e. preterm versus term born) and the individual risk of developing certain diseases.